{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:53:55Z","timestamp":1786550035958,"version":"build-2736575974"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1038\/ajg.2016.108","type":"journal-article","created":{"date-parts":[[2016,4,5]],"date-time":"2016-04-05T08:02:51Z","timestamp":1459843371000},"page":"845-851","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Safety and Efficacy of Ombitasvir\/Paritaprevir\/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents"],"prefix":"10.14309","volume":"111","author":[{"given":"Mitchell L","family":"Shiffman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Rustgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Forns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarik","family":"Asselah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon Planas","family":"Vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Pedrosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Moller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Reau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R5-27-20210210","first-page":"256A","article-title":"Treatment outcomes with 8, 12 and 24 week regimens of ledipasvirsofosbuvir for the treatment of hepatitis C infection: analysis of a multicenter prospective, observational study.","volume":"62","author":"Terrault","year":"2015","journal-title":"Hepatology"},{"key":"R6-27-20210210","first-page":"53","article-title":"Pharmacokinetics, safety and tolerability of the HCV protease inhibitor ABT-450 with ritonavir following multiple ascending doses in healthy adult volunteers.","volume":"5","author":"Bernstein","year":"2009","journal-title":"Global Antiviral J"},{"key":"R7-27-20210210","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/01.qai.0000219774.20174.64","article-title":"Lopinavirritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.","volume":"42","author":"Yeh","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R8-27-20210210","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhep.2015.01.026","article-title":"Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevirritonavir, ombitasvir, and dasabuvir.","volume":"63","author":"Menon","year":"2015","journal-title":"J Hepatol"},{"key":"R9-27-20210210","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa1315722","article-title":"Treatment of HCV with ABT-450r-ombitasvir and dasabuvir with ribavirin.","volume":"370","author":"Feld","year":"2014","journal-title":"N Engl J Med"},{"key":"R10-27-20210210","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1056\/NEJMoa1401561","article-title":"Retreatment of HCV with ABT-450r-ombitasvir and dasabuvir with ribavirin.","volume":"370","author":"Zeuzem","year":"2014","journal-title":"N Engl J Med"},{"key":"R11-27-20210210","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.","volume":"370","author":"Poordad","year":"2014","journal-title":"N Engl J Med"},{"key":"R12-27-20210210","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450r-ombitasvir and dasabuvir with or without ribavirin for HCV.","volume":"370","author":"Ferenci","year":"2014","journal-title":"N Engl J Med"},{"key":"R13-27-20210210","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1053\/j.gastro.2014.04.045","article-title":"ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97 and 100 sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.","volume":"147","author":"Andreone","year":"2014","journal-title":"Gastroenterology"},{"key":"R14-27-20210210","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1056\/NEJMoa1316366","article-title":"Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"R15-27-20210210","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.","volume":"370","author":"Afdhal","year":"2014","journal-title":"N Engl J Med"},{"key":"R16-27-20210210","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(14)61795-5","article-title":"Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.","volume":"385","author":"Lawitz","year":"2015","journal-title":"Lancet"},{"key":"R17-27-20210210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/M15-0785","article-title":"Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial.","volume":"163","author":"Zeuzem","year":"2015","journal-title":"Ann Intern Med"},{"key":"R18-27-20210210","doi-asserted-by":"crossref","first-page":"S220","DOI":"10.1016\/S0168-8278(15)30071-4","article-title":"Long-term follow-up of treatment-emergent resistance-associated variants in NS3, NS5A, and NS5B with paritaprevirr-, ombitasvir-, and dasabuvir-based regimens.","volume":"62","author":"Krishnan","year":"2015","journal-title":"J Hepatol"},{"key":"R19-27-20210210","doi-asserted-by":"crossref","first-page":"S221","DOI":"10.1016\/S0168-8278(15)30073-8","article-title":"Long-term persistance of HCV NS5A variants after treatment with NS5A inhibitor ledipasvir.","volume":"62","author":"Dvory-Sobol","year":"2015","journal-title":"J Hepatol"},{"key":"R20-27-20210210","doi-asserted-by":"crossref","first-page":"S677","DOI":"10.1016\/S0168-8278(15)31094-1","article-title":"Resistance analysis of virologic failures in hepatitis C genotype 1 infected patients treated with grazoprevirelbasvir ribavirin: the C-WORTHY study.","volume":"62","author":"Black","year":"2015","journal-title":"J Hepatol"},{"key":"R21-27-20210210","doi-asserted-by":"crossref","first-page":"S620","DOI":"10.1016\/S0168-8278(15)30976-4","article-title":"The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvirsofosbuvir RBV.","volume":"2015","author":"Sarrazin","year":"2015","journal-title":"J Hepatol"},{"key":"R22-27-20210210","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jhep.2015.04.009","article-title":"Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent.","volume":"63","author":"Forns","year":"2015","journal-title":"J Hepatol"},{"key":"R23-27-20210210","first-page":"1140A","article-title":"Safety of ledipasvirsofosbuvir with and without ribavirin for the treatment of patients with chronic HCV genotype 1 infection: an analysis of the phase 3 ION trials.","volume":"60","author":"Alqahtani","year":"2014","journal-title":"Hepatology"}],"updated-by":[{"DOI":"10.1038\/ajg.2016.202","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2016,6,30]],"date-time":"2016-06-30T00:00:00Z","timestamp":1467244800000}}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg2016108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2016108","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2016108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201606000-00027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:11:59Z","timestamp":1786547519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201606000-00027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2016.108","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]}}}